Novartis AG (NVS) P/E Ratio History
Historical price-to-earnings valuation from 2003 to 2025
Loading P/E history...
Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of February 28, 2026, Novartis AG (NVS) trades at a price-to-earnings ratio of 23.5x, with a stock price of $168.62 and trailing twelve-month earnings per share of $7.25.
The current P/E is 37% above its 5-year average of 17.1x. Over the past five years, NVS's P/E has ranged from a low of 7.4x to a high of 27.2x, placing the current valuation at the 80th percentile of its historical range.
Compared to the Healthcare sector median P/E of 23.7x, NVS is roughly in line with its sector peers. The sector includes 224 companies with P/E ratios ranging from 0.0x to 184.4x.
The PEG ratio of 1.53 (P/E divided by 22% EPS growth) suggests a fair valuation relative to its earnings growth. Peter Lynch popularized the rule that a PEG below 1.0 indicates an attractive entry point.
Relative to the broader market, NVS trades roughly in line with the S&P 500 median P/E of 26.2x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our NVS DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
Peer Comparison
P/E metrics vs. Generics and biosimilars manufacturers peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
NVSNovartis AG | $322B | 23.5 | 1.53Best | +22%Best |
OGNOrganon & Co. | $2B | 10.1Lowest | - | -78% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
Historical P/E Data
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $137.87 | $7.15 | 19.3x | +20% |
| FY2025 Q3 | Mon Sep 29 2025 00:00:00 GM | $124.10 | $7.31 | 17.0x | +6% |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $121.01 | $6.86 | 17.6x | +10% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $111.48 | $6.39 | 17.4x | +9% |
| FY2024 Q4 | $97.31 | $5.88 | 16.5x | +3% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $115.02 | $8.58 | 13.4x | -16% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $106.46 | $7.86 | 13.5x | -15% |
| FY2024 Q1 | Sun Mar 31 2024 00:00:00 GM | $96.73 | $7.38 | 13.1x | -18% |
| FY2023 Q4 | Sun Dec 31 2023 00:00:00 GM | $100.97 | $7.15 | 14.1x | -12% |
| FY2023 Q3 | Sat Sep 30 2023 00:00:00 GM | $96.39 | $3.72 | 25.9x | +62% |
| FY2023 Q2 | Fri Jun 30 2023 00:00:00 GM | $95.49 | $3.59 | 26.6x | +66% |
| FY2023 Q1 | Fri Mar 31 2023 00:00:00 GM | $87.06 | $3.25 | 26.8x | +67% |
Average P/E for displayed period: 16.0x
See NVS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NVS Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare NVS vs AGIO
See how NVS stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is NVS stock overvalued or undervalued?
NVS trades at 23.5x P/E, above its 5-year average of 17.1x. The 80th percentile ranking indicates a premium to historical valuation.
How does NVS's valuation compare to peers?
Novartis AG P/E of 23.5x compares to sector median of 23.7x. The discount suggests lower growth expectations or higher risk.
What is NVS's PEG ratio?
NVS PEG ratio is 1.53. Between 1-2 suggests valuation aligns with growth. Historical P/E data spans 2003-2025.